JAGX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of -0.13 indicates the company's liabilities exceed its assets.
- Low P/S ratio
- Negative Price/Book ratio
- No P/E or Graham Number available due to losses
Revenue growth is -7.80%, contradicting growth-based valuation models.
- Technical EPS growth due to smaller losses
- Negative YoY revenue growth
- Consistent failure to beat earnings estimates
Price performance is in a state of total collapse.
- 100% loss over 3 and 5 year horizons
- Chronic earnings misses over 25 quarters
F-Score of 1/9 is a deterministic signal of weak financial health.
- Piotroski F-Score 1/9
- Quick Ratio 0.07
- Current Ratio 0.50
Dividend Strength 0/100.
- No dividend history
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for JAGX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
Primary
|
-100.0% | -100.0% | -92.8% | -82.2% | -34.7% | -7.8% |
|
INBS
Intelligent Bio Solutions Inc.
Peer
|
-100.0% | -99.3% | -79.8% | -77.0% | -39.7% | -10.6% |
|
CLGN
CollPlant Biotechnologies Ltd.
Peer
|
-97.4% | -95.1% | -85.0% | -83.7% | -43.0% | -33.0% |
|
ISPC
iSpecimen Inc.
Peer
|
-99.9% | -99.5% | -89.9% | -85.3% | -46.7% | -9.9% |
|
ACON
Aclarion, Inc.
Peer
|
-100.0% | -100.0% | -82.0% | -56.9% | +22.9% | +1.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
BEARISH | $4.58M | - | -% | -% | $0.37 | |
|
INBS
Intelligent Bio Solutions Inc.
|
BEARISH | $4.92M | - | -150.2% | -% | $2.46 | Compare |
|
CLGN
CollPlant Biotechnologies Ltd.
|
BEARISH | $5.18M | - | -117.6% | -% | $0.36 | Compare |
|
ISPC
iSpecimen Inc.
|
BEARISH | $3.8M | - | -327.8% | -% | $0.13 | Compare |
|
ACON
Aclarion, Inc.
|
BEARISH | $3.51M | - | -97.7% | -% | $3.33 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-11 | CONTE LISA A. | Chief Executive Officer | Stock Award | 28,592 | - |
| 2025-12-11 | SIEGEL JONATHAN B | Director | Stock Award | 7,377 | - |
| 2025-12-11 | LIZAK CAROL R. | Chief Financial Officer | Stock Award | 11,740 | - |
| 2025-12-11 | WOLIN JONATHAN S | General Counsel | Stock Award | 11,740 | - |
| 2025-12-11 | JAYASURIYA ANULA | Director | Stock Award | 5,870 | - |
| 2025-12-11 | CHATURVEDI PRAVIN R | Officer | Stock Award | 11,740 | - |
| 2025-12-11 | BOCHNOWSKI JAMES J. | Director | Stock Award | 6,363 | - |
| 2025-12-11 | MICEK JOHN J III | Director | Stock Award | 7,377 | - |
| 2025-12-11 | KING STEVEN R. PH.D. | Officer | Stock Award | 11,740 | - |
Past News Coverage
Recent headlines mentioning JAGX from our newsroom.